Enzyme Technology definition

Enzyme Technology means all Intellectual Property (as defined in this Schedule 1.62) pertaining or relating to processes, compositions or relevant research, development and operating know-how for the identification, evolution and production of [*] enzymes, including but not limited to all [*], whether naturally occurring or genetically enhanced, primarily for use in processes relating to [*] Technology (as defined in this Schedule 1.62), including evolved enzymes, [*], operating protocols, computer models, samples, assay procedures, experimental reports, analytical procedures and know-how relating to the operation of fermenters.
View Source
Enzyme Technology means the development, scale-up, technical or commercial performance, on-site manufacture or supply of Roal/AB Enzymes.
View Source
Enzyme Technology means all Intellectual Property (as defined in this Schedule 1.62) pertaining or relating to processes, compositions or relevant research, development and operating know-how for the identification, evolution and production of [*] enzymes, including but not limited to all [*], whether naturally occurring or genetically enhanced, primarily for use in processes relating to [*] Technology (as defined in this Schedule 1.62), including evolved enzymes,[*], operating protocols, computer models, samples, assay procedures, experimental reports, analytical procedures and know-how relating to the operation of fermenters.
View Source

Examples of Enzyme Technology in a sentence

  • As between the Parties, Merck shall have the sole right, but not the obligation, to Prosecute all Patents disclosing and/or claiming all Arising Merck Enzyme Technology and Arising Merck Process Technology (collectively, the “Merck Patents”), in Merck’s sole discretion and at Merck’s sole cost and expense.

  • The Patent Committee shall have oversight regarding the Prosecution of Patents disclosing and/or claiming Inventions directly related to Codexis Core Technology Improvements, Merck Core Technology Improvements, Arising Merck Enzyme Technology, Arising Merck Process Technology, Arising Codexis Enzyme Technology, and Arising Codexis Process Technology, and shall provide recommendations to the Parties to maximize the value of such Patents.

  • During the Term, within [***] after the end of the Calendar Quarters ending June 30 and December 31, Merck’s representative on the Patent Committee will meet and discuss with Codexis’ representative on the Patent Committee any Codexis Core Technology Improvements, Merck Core Technology Improvements, Arising Merck Enzyme Technology, and Arising Merck Process Technology (other than any Merck API Process Technology) which Merck has developed since the last such meeting.

  • As between the Parties, Codexis shall have the sole right, but not the obligation, to Prosecute all Patents disclosing and/or claiming all Codexis Core Technology, Merck Core Technology Improvements, Codexis Core Technology Improvements, Codexis Enzymes, Codexis Libraries, Arising Codexis Enzyme Technology and Arising Codexis Process Technology (the “Codexis Patents”), in Codexis’ sole discretion and at Codexis’ sole cost and expense.

  • Codexis shall own any and all Arising Codexis Enzyme Technology and Arising Codexis Enzyme Technology IP.

  • Each Party and its Affiliates shall sign and deliver to the other Party all writings and do all such things as may be necessary or appropriate to vest in such other Party all right, title and interest in and to all Codexis Core Technology Improvements IP, Merck Core Technology Improvements, Arising Codexis Enzyme Technology IP, Arising Merck Process Technology IP, and Merck API Process Technology IP in accordance with Section 6.2.

  • Codexis shall have [***] after such meeting and receipt of the initial disclosure regarding such Codexis Core Technology Improvements, Merck Core Technology Improvements, Arising Merck Enzyme Technology, and Arising Merck Process Technology to request [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.

  • Within [***] days after the end of the Calendar Quarters ending June 30 and December 31, during the TT Term, GSK shall disclose to Codexis’ Alliance Manager [***] Arising GSK Enzyme Technology and Arising GSK Process Technology, if any.

  • The Patent Committee shall have oversight regarding the Prosecution of Patents disclosing and/or claiming Inventions directly related to Codexis Core Technology Improvements, Arising GSK Enzyme Technology, Arising GSK Process Technology, Arising Codexis Enzyme Technology and Arising Codexis Process Technology and shall provide recommendations to the Parties to maximize the value of such Patents.

  • If GSK sells, leases, loans, provides or otherwise transfers to any Third Party any asset, facility, business unit or personnel that practice or otherwise use any Codexis Core Technology, Codexis Core Technology Improvements or Enzyme Technology, GSK shall provide a certification to Codexis and Codexis shall have an audit right as set forth in Section 11.5.3.